Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.

Oncotarget · 2016 · PMC4941290 · PMID 26910118

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

Mice receiving AZD5363 demonstrated a significant decrease in the proliferation rates and a strong trend for increased apoptotic rates compared to control mice (Figure 8E ).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.